Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 1/2 1

Status

Completed 10Active not recruiting 4Terminated 3Recruiting 3Unknown 2Withdrawn 1No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 541Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Hematologic Neoplasms 264Leukemia 180Myelodysplastic Syndromes 169Leukemia, Lymphocytic, Chronic, B-Cell 168Lymphoma 101Lymphoma, Non-Hodgkin 94Recurrence 84Neoplasms 83Multiple Myeloma 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72Leukemia, Myelomonocytic, Chronic 60Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 58Burkitt Lymphoma 54Leukemia, Biphenotypic, Acute 48Myeloproliferative Disorders 45Lymphoma, Follicular 43Lymphoma, Mantle-Cell 42Lymphoma, Large B-Cell, Diffuse 42Hodgkin Disease 34Lymphoma, B-Cell 32Lymphoma, B-Cell, Marginal Zone 30Leukemia, B-Cell 30Anemia, Refractory, with Excess of Blasts 30Primary Myelofibrosis 28Leukemia, Plasma Cell 23Waldenstrom Macroglobulinemia 22Neoplasm, Residual 21Leukemia, Myeloid, Chronic-Phase 21

Interventions

obinutuzumab 1ibrutinib 1acalabrutinib 1Rituximab 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphatic Diseases × Other hematologic neoplasm × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT01451502 2026-05-08

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Masonic Cancer Center, University of Minnesota

Phase NA Recruiting
250 enrolled
Other hematologic neoplasm

Lymphatic Diseases, Hematologic Neoplasms

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Curis, Inc.

Phase 1/2 Recruiting
152 enrolled
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡